Claims for Patent: 7,078,388

Summary for Patent: 7,078,388

Title:	DNA vaccines for farm animals, in particular bovines and porcines
Abstract:	DNA vaccine against a pathogen affecting farm animals, in particular bovines or porcines, comprising a plasmid containing a nucleotide sequence encoding an immunogen of a pathogen of the animal species considered, under conditions allowing the in vivo expression of this sequence, and a cationic lipid containing a quaternary ammonium salt, of formula ##STR00001## in which R1 is a saturated or unsaturated linear aliphatic radical having 12 to 18 carbon atoms, R2 is another aliphatic radical containing 2 or 3 carbon atoms, and X a hydroxyl or amine group, this lipid being preferably DMRIE.
Inventor(s):	Audonnet; Jean-Christophe Francis (Lyons, FR), Fischer; Laurent Bernard (Sainte Foy les Lyon, FR), Barzu-Le-Roux; Simona (Lentilly, FR)
Assignee:	Merial (Lyons, FR)
Application Number:	09/760,574
Patent Claims:	1. A DNA vaccine against a bovine pathogen, wherein the bovine pathogen is BRSV, BVDV-1, BVDV-2 or bPI-3, comprising at least one plasmid that contains and expresses in a bovine host cell a nucleotide sequence encoding an immunogen of the bovine pathogen, and a cationic lipid containing a quaternary ammonium salt, of the formula ##STR00003## in which R.sub.1 is a saturated or unsaturated linear aliphatic radical having 12 to 18 carbon atoms, R.sub.2 is an aliphatic radical containing 2 or 3 carbon atoms, and X a hydroxyl or amine group. 2. The vaccine according to claim 1, further comprising DOPE. 3. The vaccine according to claim 1, further comprising bovine GM-CSF. 4. The vaccine according to claim 2, further comprising bovine GM-CSF. 5. The vaccine according to claim 1, further comprising an expression vector that contains and expresses in a bovine host cell a nucleotide sequence encoding bovine GM-CSF. 6. The vaccine according to claim 2, further comprising an expression vector that contains and expresses in a bovine host cell a nucleotide sequence encoding bovine GM-CSF. 7. The vaccine according to claim 5, wherein the expression vector is a plasmid. 8. The vaccine according to claim 6, wherein the expression vector is a plasmid. 9. The vaccine according to claim 1, wherein the nucleotide sequence encoding the immunogen of the bovine pathogen has deleted therefrom a portion encoding a transmembrane domain. 10. The vaccine according to claim 1, wherein the plasmid further contains and expresses in a bovine host cell a nucleotide sequence encoding a heterologous tPA signal sequence. 11. The vaccine according to claim 1, wherein the plasmid further contains a stabilizing intron. 12. The vaccine according to claim 11, wherein the intron is intron II of a rabbit beta-globin gene. 13. The vaccine according to claim 1, wherein the bovine pathogen is bovine respiratory syncitial virus (BRSV). 14. The vaccine according to claim 13, wherein the immunogen is BRSV F, modified by substitution of the BRSV F signal sequence with a human tPA signal sequence, and/or by deletion of the transmembrane domain. 15. The vaccine according to claim 13, the immunogen is BRSV G, modified by substitution of the BRSV G signal sequence with a human tPA signal sequence, and/or by deletion of the transmembrane domain. 16. The vaccine according to claim 2 comprising a first plasmid that contains and expresses in a bovine host cell a nucleotide sequence encoding bovine respiratory syncitial virus (BRSV) F, modified by substitution of the BRSV F signal sequence with a human tPA signal sequence and deletion of the transmembrane domain and contiguous C-terminal portion; and a second plasmid that contains and expresses in a bovine host cell a nucleotide sequence encoding BRSV G, modified by substitution of the BRSV G signal sequence with a human tPA signal sequence and deletion of the transmembrane domain and contiguous C-terminal portion; and wherein the lipid is DMRIE, whereby the vaccine comprises DMRIE-DOPE. 17. The vaccine according to claim 9, further comprising DOPE. 18. The vaccine according to claim 9, further comprising bovine GM-CSF. 19. The vaccine according to claim 9, further comprising an expression vector that contains and expresses in a bovine host cell a nucleotide sequence encoding bovine GM-CSF. 20. The vaccine according to claim 19, wherein the expression vector is a plasmid. 21. The vaccine according to claim 10, further comprising DOPE. 22. The vaccine according to claim 10, further comprising bovine GM-CSF. 23. The vaccine according to claim 10, further comprising an expression vector that contains and expresses in a bovine host cell a nucleotide sequence encoding bovine GM-CSF. 24. The vaccine according to claim 23, wherein the expression vector is a plasmid. 25. The vaccine according to claim 11, further comprising DOPE. 26. The vaccine according to claim 11, further comprising bovine GM-CSF. 27. The vaccine according to claim 11, further comprising an expression vector tat contains and expresses in a bovine host cell a nucleotide sequence encoding bovine GM-CSF. 28. The vaccine according to claim 27, wherein the expression vector is a plasmid. 29. The vaccine according to claim 13, further comprising DOPE. 30. The vaccine according to claim 13, further comprising bovine GM-CSF. 31. The vaccine according to claim 13, further comprising an expression vector that contains and expresses in a bovine host cell a nucleotide sequence encoding bovine GM-CSF. 32. The vaccine according to claim 31, wherein the expression vector is a plasmid. 33. The vaccine of claim 13 wherein the immunogen is BRSV F. 34. The vaccine of claim 13 wherein the immunogen is BRSV G. 35. The vaccine according to claim 1 or 2 wherein the lipid is DMRIE.

Details for Patent 7,078,388

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2020-01-21
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2020-01-21
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2020-01-21